Dudediligence.

Metagenomi Therapeutics, Inc

MGXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$11.5MSep ’24$9.6MDec ’24$4.1MMar ’25$8.5MJun ’25$8.7MSep ’25$3.9MDec ’25$1.2MMar ’26
Net income, by quarter
−$18.8MSep ’24−$23.4MDec ’24−$25.0MMar ’25−$19.9MJun ’25−$20.4MSep ’25−$22.5MDec ’25−$23.1MMar ’26−$27.5MJun ’26
Fiscal years, by the month each ended
LineDec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on file$44.8M$52.3M$25.2M
Operating incomenone on file−$78.5M−$88.9M−$96.0M
Net incomenone on file−$68.3M−$78.1M−$87.9M
Operating cash flownone on file−$91.4M−$109.1M−$88.9M
Free cash flownone on file−$101.2M−$112.2M−$89.5M
Cash$190.5M$140.6M$27.4M$41.7M
Shares outstandingnone on file3.4M37.4M37.6M